Use of the SEER Cancer Registry for technology assessment.
The Surveillance, Epidemiology, and End Results (SEER) cancer registry contributed to technology assessment by providing population-based samples for detailed case-control studies, by serving as the control group in comparisons with various experimental groups, by allowing an assessment of selection bias in clinical trials, and by facilitating evaluations of classification and coding systems.
Klawansky
S
S
Harvard School of Public Health.
Burdick
E
E
Adams
M
M
Bollini
P
P
Orza
M
M
Falotico-Taylor
J
J
D016208:Databases, Factual / Q000706:statistics & numerical data*; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D011159:Population Surveillance / Q000379:methods*; D012042:Registries; D013673:Technology Assessment, Biomedical / Q000379:methods*; D014481:United States